Swiss National Bank Acquires 35,600 Shares of Novavax, Inc. (NASDAQ:NVAX)

Swiss National Bank boosted its position in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 14.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 283,400 shares of the biopharmaceutical company's stock after purchasing an additional 35,600 shares during the period. Swiss National Bank owned about 0.18% of Novavax worth $2,279,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVAX. E Fund Management Co. Ltd. raised its stake in Novavax by 5.1% in the fourth quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company's stock valued at $204,000 after buying an additional 1,219 shares during the period. Bank of New York Mellon Corp raised its stake in Novavax by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company's stock valued at $3,509,000 after acquiring an additional 1,664 shares during the period. Victory Capital Management Inc. raised its stake in Novavax by 12.0% in the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company's stock valued at $244,000 after acquiring an additional 2,072 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Novavax by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 3,174 shares during the period. Finally, Spire Wealth Management bought a new position in Novavax during the fourth quarter worth $29,000. Institutional investors own 53.04% of the company's stock.

Remove Ads

Novavax Trading Down 8.4 %

Shares of NASDAQ:NVAX traded down $0.59 on Monday, reaching $6.41. 4,623,351 shares of the company's stock were exchanged, compared to its average volume of 8,025,169. Novavax, Inc. has a twelve month low of $3.81 and a twelve month high of $23.86. The company has a fifty day moving average of $8.09 and a 200-day moving average of $9.28. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -2.84, a PEG ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same quarter last year, the business earned ($1.44) EPS. As a group, equities research analysts forecast that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NVAX has been the subject of a number of research reports. TD Cowen upgraded shares of Novavax to a "hold" rating in a research note on Thursday, February 27th. BTIG Research assumed coverage on shares of Novavax in a research report on Friday, February 28th. They set a "buy" rating and a $19.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Novavax presently has an average rating of "Hold" and an average target price of $18.00.

Insider Activity at Novavax

In other Novavax news, Director James F. Young sold 5,400 shares of the firm's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the transaction, the director now directly owns 51,760 shares of the company's stock, valued at $414,080. This trade represents a 9.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.00% of the stock is owned by insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.